Keros Therapeutics (NASDAQ:KROS) Stock Rating Raised to “Strong-Buy” at Zacks Research

Zacks Research upgraded shares of Keros Therapeutics (NASDAQ:KROS) from a hold rating to a strong-buy rating in a research note published on Monday morning,Zacks reports.

Other equities analysts also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Tuesday. Wall Street Zen raised shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Keros Therapeutics in a report on Tuesday, August 4th. Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 4th. Finally, Leerink Partners reduced their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $21.40.

Keros Therapeutics Price Performance

KROS opened at $9.33 on Monday. Keros Therapeutics has a 12 month low of $8.98 and a 12 month high of $22.55. The stock has a market capitalization of $183.05 million, a price-to-earnings ratio of -3.31 and a beta of 1.13. The business has a fifty day moving average price of $11.11 and a 200 day moving average price of $11.82.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.96) by $1.66. The company had revenue of $40.01 million for the quarter, compared to analyst estimates of $14.76 million. Keros Therapeutics had a negative return on equity of 21.85% and a negative net margin of 256.60%. On average, research analysts anticipate that Keros Therapeutics will post -4.45 earnings per share for the current year.

Keros Therapeutics announced that its board has authorized a stock repurchase program on Wednesday, September 9th that allows the company to repurchase $5 million in outstanding shares. This buyback authorization allows the company to reacquire up to 2.3% of its shares through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Transactions at Keros Therapeutics

In related news, insider Lorena Raquel Lerner sold 3,568 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the transaction, the insider directly owned 27,559 shares of the company’s stock, valued at $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,343 shares of company stock valued at $54,985 over the last three months. Corporate insiders own 12.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of KROS. BlackRock Inc. purchased a new position in shares of Keros Therapeutics in the 2nd quarter valued at $29,898,000. Nantahala Capital Management LLC purchased a new stake in Keros Therapeutics in the second quarter valued at $15,091,483. Dimensional Fund Advisors LP boosted its stake in Keros Therapeutics by 453.9% in the first quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock valued at $3,547,000 after acquiring an additional 263,347 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in Keros Therapeutics in the second quarter valued at $2,641,000. Finally, Man Group plc acquired a new position in Keros Therapeutics in the second quarter valued at $1,664,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

More Keros Therapeutics News

Here are the key news stories impacting Keros Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target while raising its 2026 and 2027 earnings estimates. Separately, Zacks said KROS’s roughly 21% decline over four weeks had pushed it into oversold territory, which could leave room for a rebound if selling pressure eases. Zacks article
• Neutral Sentiment: A report listed short interest at zero shares and a zero-day short-interest ratio. The figure offers little indication of short-selling pressure, though it conflicts with the entry’s description of a large increase.
• Negative Sentiment: Keros is still forecast to report losses, and HC Wainwright trimmed its 2028–2030 earnings estimates. Those revisions point to ongoing uncertainty about the pace of the company’s path to profitability.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function. Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.